Louis Garrot, MD
Hematology & Oncology · Marietta, GANPI 1609941335
Payments from drug & device makers
Across 245 payments — averaging $5386.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$753K
- Eli Lilly$301K
- Merck$125K
- Genentech, Inc.$103K
- Seagen Inc.$27K
- Eisai Inc.$3K
- plus $7K from 31 others
What the payments were for
- Consulting fees$5,54031%
- Speaking & faculty fees$7,01040%
- Travel & lodging$1,1887%
- Food & beverage$3,55520%
- Education$4152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 31 | $753,468 |
| Eli Lilly | 16 | $301,012 |
| Merck | 17 | $125,336 |
| Genentech, Inc. | 16 | $102,971 |
| Seagen Inc. | 4 | $26,962 |
| Eisai Inc. | 10 | $3,376 |
| Daiichi Sankyo Inc. | 43 | $1,627 |
| Bristol Myers Squibb | 4 | $1,242 |
| Bayer | 3 | $928 |
| AstraZeneca | 13 | $354 |
| Pfizer | 18 | $340 |
| Astellas Pharma US Inc | 6 | $329 |
| Exelixis Inc. | 5 | $238 |
| AbbVie | 4 | $236 |
| Johnson & Johnson | 7 | $182 |
| Sanofi | 3 | $172 |
| Amgen | 2 | $133 |
| Novartis | 5 | $126 |
| Array Biopharma Inc | 9 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $75 |
| Gilead | 3 | $74 |
| Incyte Corporation | 3 | $58 |
| Lilly USA, LLC | 2 | $49 |
| Sobi, Inc | 2 | $48 |
| GSK | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Acrotech Biopharma Inc. | 2 | $41 |
| EMD Serono, Inc. | 1 | $40 |
| Beigene USA, Inc. | 2 | $39 |
| Blueprint Medicines Corporation | 1 | $32 |
| Genentech USA, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,319,798 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 74 | $985,540 |
| RevlimidLenalidomide | 39 | $626,219 |
| CalquenceAcalabrutinib Maleate | 28 | $415,921 |
| InlytaAxitinib | 15 | $256,071 |
| PomalystPomalidomide | 12 | $252,041 |
| VenclextaVenetoclax | 17 | $244,943 |
| OrgovyxRelugolix | 86 | $243,149 |
| BrukinsaZanubrutinib | 20 | $240,011 |
| JakafiRuxolitinib Phosphate | 12 | $196,788 |
| LonsurfTrifluridine/Tipiracil Hcl | 16 | $179,581 |
| ErleadaApalutamide | 12 | $177,549 |
| NinlaroIxazomib Citrate | 12 | $158,050 |
| Abiraterone Acetate | 50 | $133,779 |
| EliquisApixaban | 137 | $107,202 |
| XareltoRivaroxaban | 59 | $62,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $928 | $985,54074 claims |
| Bristol Myers SquibbRevlimid | $1,242 | $626,21939 claims |
| AstraZenecaCalquence | $354 | $415,92128 claims |
| PfizerInlyta, Eliquis | $340 | $363,273152 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $753,468 | $252,04112 claims |
| AbbVieVenclexta | $236 | $244,94317 claims |
| Beigene USA, Inc.Brukinsa | $39 | $240,01120 claims |
| Johnson & JohnsonErleada, Xarelto | $182 | $239,69371 claims |
| Incyte CorporationJakafi | $58 | $196,78812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $75 | $158,05012 claims |
| Lilly USA, LLCOlanzapine | $49 | $26517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Marietta
- Steven McCuneMarietta$19.5M
- Raul OyolaMarietta$2.1M
- Dean KirkelMarietta$898K
- Zulfiqar MalikMarietta$824K
- Gena Volas ReddMarietta$742K
- Mehmet BilenAtlanta$21.7M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.